非重症嗜酸性肉芽肿性多血管炎的长期结局:缓解诱导试验后的随访分析
本研究对50例非重症新诊断嗜酸性肉芽肿性多血管炎(EGPA)患者进行中位6.3年的前瞻性随访,评估1年硫唑嘌呤(AZA)联合糖皮质激素诱导缓解后的长期结局。结果显示5年血管炎复发率为48%,孤立性哮喘/鼻窦加重(IARE)率为56%,两组间无差异,且无基线参数与结局相关。结论认为1年AZA联合GC诱导治疗未带来长期获益。
要点
- 非重症EGPA患者1年AZA联合GC诱导治疗未改善长期复发率。
- 5年血管炎复发率48%,IARE率56%,两组间无显著差异。
- 血管炎复发多发生在头2年,IARE贯穿随访全程,需其他预防治疗。
核心结论
- 1年AZA联合GC诱导治疗对非重症EGPA患者获得良好总体生存,但无长期获益。
- 血管炎复发多发生在头2年,IARE贯穿随访全程,需要其他预防性治疗。
研究设计与样本
- 对先前对照试验中50例非重症新诊断EGPA患者进行前瞻性随访,中位随访6.3年(IQR 5.4-7.6)。
- M24后根据医生最佳判断治疗,记录 flares 和增加GC或免疫抑制剂的原因,按随机分组回顾区分血管炎复发与IARE。
主要发现
- 50例参与者中2例(4%)在纳入后11个月死亡,另1例在纳入后4.8年因感染死亡。
- 至M24,血管炎复发21/49(43%),IARE 14/50(28%)。
- 后续9例血管炎复发中3例为大复发,3例首次复发在M24后;25例later IARE中17例发生在M24后。
- 5年血管炎复发率为48%(95%CI 34.0, 62.6),IARE率为56%(95%CI 41.7, 70.8),两组间无差异(P=0.32和0.13)。
- 随访期间无入口临床或生物学参数与这些结局相关。
临床怎么用
- 非重症EGPA患者1年AZA联合GC诱导后仍需长期监测血管炎复发和IARE。
- 血管炎复发多集中在头2年,IARE贯穿全程,应考虑其他预防性治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In a previous controlled trial, 1-year adjunction of AZA to glucocorticoids (GC) for patients with non-severe, newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) failed to lower remission failure, vasculitis relapse and isolated asthma/rhinosinus exacerbation rates, or cumulative GC use at month (M) 24. The aim of this study was to analyse longer-term outcomes to determine whether subsequent vasculitis relapse or isolated asthma/rhinosinus exacerbation (IARE) rates differed. METHODS: After M24, patients were followed prospectively, being treated based on physicians' best judgment. Flares and reasons for increased GC dose or immunosuppressant use were recorded, and reviewed according to randomization group to distinguish vasculitis relapses from IAREs according to EGPA Task Force recommendations. RESULTS: Fifty EGPA trial participants were followed for a median (interquartile range) of 6.3 (5.4-7.6) years; two (4%) died 11 months post-inclusion. By M24, vasculitis had relapsed in 21/49 (43%) patients and 14/50 (28%) had IAREs. Another patient died 4.8 years post-inclusion (infection). Among nine patients with subsequent vasculitis relapses, three had a major relapse and three had their first relapse after M24; among 25 patients with later IAREs, 17 occurred after M24. At 5 years, respective vasculitis relapse and IARE rates were 48% (95% CI 34.0, 62.6) and 56% (95% CI 41.7, 70.8), with no between-arm differences (P = 0.32 and 0.13). No entry clinical or biological parameter was associated with these outcomes during follow-up. CONCLUSION: These results confirmed that 1-year AZA and GC induction obtained good overall survival but no long-term benefit for non-severe EGPA patients. Vasculitis relapses, occurring mostly during the first 2 years, and IAREs, occurring throughout follow-up, require other preventive treatments. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00647166.
引用
- Puéchal X, Pagnoux C, Baron G, et al. Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. Rheumatology (Oxford). 2019. PMID: 31056661. doi:10.1093/rheumatology/kez139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。